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1. Introduction  
In recent past, the potential use of stem cells and the advancement in stem cell research for 
Regenerative Medicine is considered as an alternative therapeutic strategy for a broad range 
of genetic and acquired diseases.   
The interest in stem cells has been increasing over the past years, since their discovery in the 
early ’90s, and they might represent a promising tool for regenerative purposes because of 
their capability to become almost any cell of an adult organism.  
Despite the discoveries and the promising results, many are the controversies raised by stem 
cells. Feasibility of their use for human therapeutic purposes is regulated by many 
requirements such as safety, accessibility to a source that can provide an adequate amount 
of cells for in vitro expansion, absence of ethical issues and repeatability of the results. 
Different lines of stem cells are investigated for understanding the basic mechanism of 
cellular differentiation and the potential for regenerative medicine purposes. However, to 
overcome safety and ethical issues, scientists are still looking for alternative sources that 
may provide easy and safe access to a cell population that may be used for cellular therapy. 
Amniotic fluid, due to its contact with the fetus, has been considered an interesting source 
for undifferentiated or partially differentiated cells.  
More recently, interest has been rising on more committed cell lines that may possibly 
provide new, more specific, tools for tissue regeneration. In particular, the isolation of cells 
already committed to a specific fate has been performed for kidney, pancreas and other 
organs and the study of these novel cell populations may give us an insight on cellular 
development and provide a more precise way of driving cell differentiation into a mature 
cell type.   
Nevertheless, our knowledge of amniotic fluid cellular composition is still incomplete and 
only in the last few years some studies have been published describing the different cell 
types that can be retrieved. As long as new discoveries are shared and new insights are 
given on amniotic fluid cellular composition and cell differentiation we can gain a better 
understanding of the mechanism underlying development. The main goal of this chapter is 
to provide the readers with a broad knowledge regarding the work that has been done until 
now to undisclose the heterogeneous amniotic fluid cellular composition and their use for 
regenerative medicine purposes. 
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2. Amniotic fluid 
Amniotic fluid is a clear, fluid that fills the amniotic cavity. It provides an ideal and 
protective environment in which floats the developing embryo and later on the fetus. It also 
helps to regulate the temperature of the fetus during the pregnancy. 
2.1 Origin and molecular composition 
During embryogenesis, maternal plasma is the main protagonist of amniotic fluid volume 
increase and water flows osmotically through fetal membranes, and, later on, through the 
placental membrane. The volume and the composition change during pregnancy following 
the physiological variations of the developing fetus (Fig. 1).  
 
 
Amniotic fluid composition and volume are the result of exchanges and interaction with many different sources, 
either fetal or maternal. the above figure shows a schematic representation of the most important overall 
contributions to amniotic fluid. 
Fig. 1. Amniotic fluid origin and composition 
During the first weeks of gestation, the composition is comparable to the fetal plasma and its 
volume increases from 25 ml at 10 weeks to about 400 ml at 20 weeks (Underwood et al., 
2005). By 8 weeks of gestation the fetal kidney begins fluid production that rapidly increases 
in volume during the second trimester.  The exchange of fluids through the skin is present 
until keratinisation that occurs between 20 and 24 weeks of gestation. The molecular 
composition and the presence of nutritive substances have been shown to play a key role, in 
animals, in the proliferation and differentiation of various intestinal cell types such as 
epithelial and mucosa cells (Underwood et al., 2005).  
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2.2 Amniotic fluid in diagnostic  
The use of amniotic fluid to determine the status of health of the fetus has been an important 
diagnostic tool for many years. Back in the 60s, it was considered an invaluable source of 
information for the diagnosis of fetal distress, haemolytic disease and fetal maturity (Horger 
et al., 1969), neural tube defects and lung maturity (Underwood et al., 2005).  Over the years, 
the diagnostic techniques have been greatly improved and new fields of investigation have 
tried to tie various conditions with preterm labour, infective processes and embryo diseases.  
In particular, it has been used as a safe and reliable screening tool for genetic and congenital 
diseases in the fetus.  
2.3 Isolation, expansion and characterization of amniotic fluid cells 
The possibility of using amniotic fluid derived pluripotent and multipotent stem cells has 
been found appealing due to the relative easiness and safe procedure required to retrieve 
the cells from its source. Furthermore, the use of multipotent progenitors has been 
considered an attractive alternative to the use of pluripotent cells due to their already 
committed phenotype. Cells can be isolated from the liquid collected by amniocentesis. 
Briefly, prior to amniocentesis an ultrasound is performed to confirm fetal viability, 
gestational age, number of fetuses, placental location, volume, fetal anatomical survey, 
uterine cavity abnormalities and to evaluate the best needle insertion site.  
A 20 cc syringe is used to aspirate the liquid.  The first 2 cc collected should be discharged 
and then using another syringe and then, using another syringe, additional 15 to 20cc are 
aspirated.. Removal of the fluid generally takes less than 1 minute. After collection the cells 
are seeded with specific culture media and the adherent fraction is expanded. 
Contact between amniotic fluid and compartments of the developing fetus, such as lung and 
gastrointestinal tract can explain the presence of different types of cells (Fig. 2).  Moreover, 
cells detaching from the forming kidney or exfoliating from the fetal skin may contribute 
significantly to cellular composition. In particular, the presence of mature cell lines derived 
from all three germ layers has been identified (Hoehn et al., 1982; Gosden et al., 1983).  
Mesenchymal and hematopoetic progenitor cells have also been shown to exist before the 
12th week of gestation in humans (Torricelli et al., 1993) together with cells expressing 
proteins and various genetic markers from specific tissue types including brain, heart, and 
pancreas have all been discovered (Tsangaris et al., 2004, Bossolasco et al., 2006; McLaughlin 
et al., 2006; Da Sacco et al., 2010).  
Fauza et al. reported the successful isolation and expansion of unfractioned mesenchymal 
stem cells (AFMC) from human samples between 20 and 37 weeks of gestation, confirming 
the presence of a multipotent mesenchymal cell types over the progression of gestation 
(Kunisaki et al., 2007).  A fully characterization of amniotic fluid pluripotent cell population 
has first been reported by Atala in 2007 (De Coppi et al., 2007).  This newly isolated stem cell 
population (AFSC) is characterized by expression of c-kit, a surface marker expressed by 
stem cells of mesenchymal origin. AFSC  express some surface markers and transcription 
factors distinctive of ESC such us OCT-4 and  SSEA-4 indicating they can actually posses 
some important characteristics that also ESC have, showing their pluripotential capability. 
They stained positively for a number of surface markers characteristic of mesenchymal 
and/or neural stem cells, including CD29, CD44 (hyaluronan receptor), CD73, CD90 and 
CD105 (De Coppi et al., 2007). 
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Amniotic fluid cells can be easily collected and expanded in vitro and exhibit a heterogeneous morphology with a 
preponderance of fibroblastoid, mesenchymal like cell shape (Unpublished Picture, Da Sacco et al.) 
 
Fig. 2. Amniotic fluid cells morphology 
However, a comprehensive analysis of amniotic fluid cellular composition has been 
missing and only in 2010 Da Sacco et al. for the first time demonstrated that the cellular 
composition varies in a timely fashion (Fig.3). Expression of markers for cells belonging to 
early endodermal and mesodermal germ layer differentiation pathway is predominant in 
the earlier weeks of gestation and constantly decreases over time to disappear at 17-18 
weeks of gestation. Ectodermal markers, probably because of the exfoliating fetal skin, 
maintain a stable expression in all the samples analyzed. Interesting, it is shown that 
concurrent with the decrease of germ layers markers there is a noticeable increase of 
organ specific progenitor cell marker expression. Proteins expressed during lung, liver, 
heart and kidney differentiation are highly expressed starting form 17-18 weeks while 
expression of pluripotent markers such as OCT-4 and c-kit was found stable over time in 
all the samples analyzed, suggesting that, at least in the time range analyzed, the 
pluripotent cells are undergoing self renewal. Furthermore, mesenchymal marker CD90 is 
present in all the samples analyzed while hematopoietic marker CD34 decreased its 
expression over time. 
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Mesodermal and endodermal cellular markers decrease over time and are not detectable after 17-18 weeks of 
gestation while various organ progenitor cell markers concentration rise after 17-18 weeks. Pluripotent markers 
OCT-4 and c-kit remain unchanged, as well as ectodermal markers, probably because of skin exfoliation. CD34 
cellular marker rises after 18 weeks of gestation.  
Fig. 3. Schematic representation of changes in composition within amniotic fluid between 15 
and 20 weeks of gestation. (Da Sacco et al., 2010) 
3. Amniotic fluid cells and organ specific regenerative medicine 
Due to an easy and safe collection procedure, amniotic fluid has quickly gained interest as a 
potential source of pluripotent/multipotent cells for regenerative medicine purposes. 
Amniotic fluid stem cells have been shown to be easily cultured and expanded upon 
collection and isolation De Coppi et al., 2007, Perin et al., 2007, Da Sacco et al., 2010, 
Kunisaki et al., 2007). De Coppi et al. (De Coppi et al., 2007) and Arnhold et al. (Arnhold et 
al. 2011) proved that after c-kit selection these cells are still exhibiting optimal growth rate. 
Their potential for differentiation has been proved in many published works and cells can 
be retrieved from different species like humansDe Coppi et al. 2007, Perin et al., 2007, Da 
Sacco et al., 2010), pigs (Zheng et al., 2010), goat (He et al., 2011; Zheng et al., 2011 ), mouse 
(De Coppi et al., 2007 ) and buffalo (Yadav et al., 2010).  
A recent report following a comparative analysis of AFSC and BM-MSC cells on 
proliferative potential and immunogenicity analysis showed the AFSC are less 
immunogenic and harbor a higher proliferation rate than BM-MSC (Mirebella et al., 2011). 
3.1 Amniotic fluid cells and kidney 
The complexity of the kidney and the multiple functions of the renal compartment are a 
great challenge to a successful therapeutic approach for its recovery and the regeneration. 
Beside the use of endogenous stem cells and other traditional and advanced therapies, the 
administration of exogenous stem cells, including AFSC has been proposed (Perin et al., 
2011).  
In the recent past, Perin et al. showed the capability of AFSC to participate in vitro to the 
development of embryonic kidneys. In particular, cells labeled with the surface marker CM-
Dil were shown able to integrate within the structures of the developing kidney. Integration 
into the metanephric structures was additionally confirmed by the migration of the injected 
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cells to the periphery of the embryonic kidney. This data strongly correlates to the 
centrifugal pattern of induction, morphogenesis and differentiation of the metanephros, 
proceeding from the center to the periphery of the embryonic organ (Perin et al., 2007).  
Moving into an in vivo model, the same group for the first time proved the potential of 
human AFSC to participate to the regeneration of kidneys undergoing acute tubular 
necrosis (Perin et al., 2010). After intra renal injection, cells were showed to survive, 
integrate into renal structures, and differentiate into tubular cells expressing proximal as 
well as distal epithelial tubular markers and persist over the long term.  
However, as the Authors highlight in their study, the main mechanism of action seems to lie 
into the ability of AFSC to modulate the immune response by lowering pro-inflammatory 
cytokines while stimulating the expression of anti inflammatory molecules, and by lowering 
apoptosis and increasing endogenous proliferation.  
On a different model of acute renal injury, Camussi’s research group confirmed the positive 
results and the comparable efficacy between BM-MSC and AFSC (Hauser et al., 2010).  
Beside the use of pluripotent cells, in 2010, we reported the isolation and characterization of 
more committed Amniotic Fluid derived Kidney Progenitor Cells (AFKPC) (Da Sacco et al., 
2010). Cells expressing both CD24 and OB-Cadherin were sorted and characterized for a wide 
range of kidney markers such as PAX-2, LIM-1, GDNF, ZO-1. Additional selections were 
performed on the CD24+OB-cadherin+ cells to isolate cells committed to mesangial 
differentiation, podocyte differentiation, mesenchymal to epithelial transition cells and 
vascular progenitors. Characterization of marker expression for these subpopulations showed 
significant differences in gene expression, confirming their different commitment to renal fate.  
3.2 Amniotic fluid cells and lung 
In uterus, the developing lungs of the fetus are filled with fetal lung liquid which is actively 
secreted into the amniotic fluid.  In the late gestational period, surfactant produced by the 
fetal lungs contributes to the composition of amniotic fluid and can be measured to 
determine the developmental stage of the surfactant system within the organ.  Contact 
between the developing lung and the fluid make it a possible important reservoir for cells to 
be used in lung regenerative medicine. In fact, AFSC were shown able to integrate and 
proliferate into mouse embryonic lung and express human lung epithelial cell markers 
(Carraro et al., 2008).  
Following hyperoxia injury, a tail vein injection of cells into nude mice showed localization 
in the distal lung with expression of both TTF1 and type II pneumocyte marker surfactant 
protein C. In the same work, specific Clara cells damage through naphthalene injury was 
followed by integration and differentiation of AFSC at the bronchioalveolar and bronchial 
positions with expression of specific Clara cell 10-kDa protein  (Carraro et al., 2008). The 
positive results obtained by Warburton’s research group were the first to prove the use of 
AFSC for in vivo organ regeneration. However, as underlined by the author, the number of 
cells homing and integrating within the lung was considerably low and the effects on tissue 
regeneration may be due on mechanisms different from integration and proliferation. 
However, our knowledge on this field is still lacking and more studies should be performed 
to clarify molecular pathways and suggest a plausible mechanism of action.  
3.3 Amniotic fluid cells and heart 
Heart failure remains one of the major causes of mortality in the United States (Honold et 
al., 2004). Stem cells have been proposed as an alternative, innovative approach for the 
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treatment of heart disease and cardiac differentiation. AFSC have been tested in the past 
years for their potential of becoming functional cardiomyocytes. 
Hoerstrup’s research group used amniotic fluid derived cells to successfully repopulate 
heart valves. After isolation, CD133- and CD133+ cells were isolated, characterized and 
subsequently seeded onto tissue engineered scaffolds. Feasible heart valve leaflets were 
obtained in vitro with the use of both fibroblast-like and endothelial like cells (Schmidt et al., 
2007). However, Chiavegato et al., in 2007 showed that injections of human AFSC into a rat 
normal or ischemic myocardium was ineffective and cells were targeted by the immune 
response with consequent rejection of the xenotransplanted cells. On the other hand, the use 
of a xenotransplantation model, even when cells were injected in immunodeficient animals, 
may not be ideal for immunogenicity studies. 
New insights on the cardiomyogenic potential of amniotic fluid cells have been published in 
2010 by Soker et al. showing the in vitro capability of AFSC to be differentiated into cardiac 
cells when co-cultured with rat cardiomyocytes (Guan et al., 2010). Along with this work, 
Sung’s research group reported the differentiation of AFMC into cardiomyocytes and 
endothelial cells (Yeh et al., 2010). Bollini et al. in two different works demonstrated the 
potential of AFSC to differentiate into cardiomyocytes both in vitro (Bollini et al., June 2011) 
and in vivo showing their cardioprotective effect following acute myocardial infarction 
(Bollini et al., May 2011).  
In summary, the results obtained with amniotic fluid derived stem cells for cardiomyocyte 
differentiation are contrasting, mostly due to the lack of a specific model and the use of 
different species and differentiation protocols. More studies should be performed in order to 
truly confirm their capability to provide an effective tool for cardiovascular regenerative 
medicine.  
3.4 Amniotic fluid cells and hematopoietic system 
C-kit positive/ Lin – cells derived from both human and mouse, have been shown to have 
hematopoietic potential (Ditadi et al., 2009). These cells were capable of differentiating into 
erythroid, myeloid, and lymphoid lineages in vitro as well as in vivo, in the peripheral 
blood of irradiated mice. Furthermore, single cells analysis was able to assess the expression 
of several genes important during different stages of hematopoietic differentiation.  
3.5 Amniotic fluid cells and pancreas 
The occurrence of pancreatic damage and diabetes has dramatically increased in the last 
years. The rise of this emergency has strongly encouraged physicians and scientist to search 
for alternative therapeutic approaches. In 2009 was suggested that stem cells derived from 
amniotic fluid could be of use for pancreatic regeneration (Furth et al., 2009).  
However, the first attempts to differentiate amniotic fluid cells into functional pancreatic 
cells were unsuccessful. In fact, the use of obestatin, a molecule proven to efficiently increase 
expression of pancreatic beta cell genes, was unable to stimulate pdx-1 expression these cells 
(Trovato et al., 2009).  
A better knowledge of developmental pathways and gene cascades involved in pancreatic 
specification brought, a year later, to a growing number of successes. In fact, differentiation 
into pancreatic cells was proven using a variety of different procedures. In particular, 
transfection with the PDX-1 gene was able to induce pancreatic features on cells from AFMC 
(Gage et al., 2010).  
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With an interesting approach, Li et al. were able to prove differentiation into insulin 
producing cells by silencing several neuronal genes by use of small interference NRSF RNA. 
This was shown as crucial for pancreatic differentiation and for the expression of pancreatic 
markers including Pdx1, Hnf4┙, Isl-1, Nkx6.1, Insulin, and Glut (Li et al., 2010).  A different 
approach was taken by Zou et al.  Knowing that the expression of particular surface markers 
can identify cell populations with specific traits and defined commitment, a CD44+/CD105+ 
population was isolated and successfully differentiated into pancreatic cells expressing 
PDX-1 (Zou et al., 2011). The increasing number of studies reported in the last two years 
suggests that the interest for amniotic fluid cells for beta cell differentiation is a growing 
research subject. Moreover, differentiation into pancreatic beta cells is been proven as 
possible in vitro settings. However, no in vivo studies have been published reporting their 
potential in acute and chronic pancreatic diseases. 
3.6 Amniotic fluid cells and brain 
The differentiation of pluripotent and multipotent cells into neural cells has been considered 
fundamental for understanding brain differentiation and for the establishment of innovative 
approaches for the healing of brain injuries. Many different studies have been performed on 
amniotic fluid cells and their expression of neuronal markers. However, their ability to 
differentiate into functional brain cells has being highly debated.  
First reports on amniotic fluid progenitor cells commitment to neuronal cell lineage were 
published in 2006. In fact, McLaughlin’s research group reported the ability to isolate and 
expand them in culture. Their studies showed that these novel progenitors are committed to 
mesencephalic dopaminergic neurons (McLaughlin et al., 2006). AFMC  were shown to be 
able to differentiate into brain cells both in vitro (Prusa et al., 2004, Tsai et al., 2004; Tsai et 
al., 2007; Jiang et al., 2010, Mareschi et al., 2009)  and in vivo (Cheng et al., 2010). Selection of 
specific cell population based on specific surface marker expression didn’t show to really 
improve the neuronal potential of amniotic fluid cells. Cells isolated by use of different 
surface markers like c-kit, (De Coppi et al., 2007),  sox-2 (Jezierski et al., 2010)  were shown 
able to differentiate into neuronal like cells.  However, in 2009 was reported the inability of 
AFSC to differentiate into dopamine neurons both in vitro and in vivo assays (Donaldson et 
al., 2009). An interesting recent study, investigated the impact of extracellular signals on 
neural differentiation, where it was confirmed that extracellular matrix has an essential role 
on neurogenic differentiation and therefore regulates its efficiency (Orciani et al., 2011).  
While many studies seems to prove that differentiation of amniotic fluid stem cells, either 
AFSC or AFMC, into neural cell types, there are still too many open questions about 
functionality of the differentiation, ideal cell population and best differentiation cocktail. 
While the current status of the research gives great hope for the future, to confirm of deny 
the possible use of amniotic fluid cells for brain regeneration more in vitro and in vivo data 
are certainly required.   
3.7 Amniotic fluid cells and liver 
Only a few studies have been reported that investigate the potential of amniotic fluid 
derived cells for hepatocyte differentiation. Zheng et al. in their work, claimed that AFSC 
had a better response to the differentiation when compared with BM-MSC under the same 
conditions (Zheng et al., 2008). Later on, differentiation into the hepatic lineage was 
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successfully obtained by Gasbarrini research group (Saulnier et al., 2009) that showed the 
equal potential of adult and fetal derived cells, including AFSC, for liver regeneration. 
However, beside these encouraging results, more studies are required prior to confirm the 
suitability of amniotic fluid stem cells for liver therapy.  
3.8 Amniotic fluid cells and bone  
In 2010, it was reported a positive effect of transient ethanol exposure during early 
differentiation of AFSC into osteoblasts (Hipp et al., 2010).  
Papaccio’s research group showed the ability of AFMC to differentiate into bone cells when 
co-cultured with dental pulp cells proving potential for bone engineering (De Rosa et al., 
2010).  
Osteogenic progenitors have been found within amniotic fluid (Antonucci et al., February 
2009).  In this work, they were able to obtain calcium mineralization and osteogenic 
differentiation of AFMC. Expression of various osteogenic markers after 30 days in culture 
was demonstrated. Similar results were obtained by two other research groups (Antonucci  
et al., October 2009, Steigman et al., 2009 and Sun et al., 2010).  
Peister in 2011 showed that AFSC  were capable of a greater differentiation potential 
compared to mesenchymal stem cells although the latter response to the differentiative 
cocktail was occurring at earlier times (Peister et al., 2011). However, in vivo data are still 
lacking and the osteogenic potential of amniotic fluid cells in a complex environment should 
be undisclosed. 
3.9 Amniotic fluid cells and chondrocytes, adipose tissue and skeletal muscular 
cellular differentiation 
3.9.1 Chondrocytes  
The regenerative capacity of the cartilage is limited. The ability to differentiate stem cells 
into cartilage may provide a better alternative to primary culture of chondrocytes that in 
vitro dedifferentiate losing their characteristics (Kramer et al., 2008). 
Fauza’s research group demonstrated the ability of ovine AFMC to successfully differentiate 
into chondrocytes on 3D scaffolds expressing several markers of cartilage (Kunisaki et al., 
2006). Atala’s group showed the ability of AFSC to differentiate into chondrocytes (De 
Coppi et al., 2007). However, no functional studies were performed to confirm the possible 
use of these amniotic fluid derived cartilage cells.  
3.9.2 Adipocytes 
Adipocyte differentiation was proven in 2007 for AFSC when these cells were first 
characterized and tested for their pluripotentiality (De Coppi et al., 2007). 
In addition,  adipogenic differentiation for goat derived AFMC was shown in 2011 (He et al., 
2011) proving their differentiative potential.  
3.9.3 Myocytes 
Muscular tissue is well known to harbour endogenous stem cells that help recovering the 
tissue after an injury. However, the differentiation potential of these pluripotent stem cells 
and when the extent of the injury, due to an acute or chronic insult, is too heavy, muscular 
degeneration occurs with loss of motility and impaired function. The study of cells feasible 
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for muscular differentiation and regeneration has been considered essential for a successful 
therapeutic approach.  
Amniotic fluid cells have been studied for their capability to differentiate into functional 
muscular cells. In particular,  Streubel  reported using non-hematopoetic AFMC for the 
conversion of amniocytes into myocytes. (Streubel et al., 1996). De Coppi  showed the ability 
of AFSC to differentiate into myocites in vitro by expression of markers expressed by the 
differentiating and mature muscle fibers (De Coppi et al., 2007) and the results were later 
confirmed by studies both in vitro and in vivo on scid mice (Gekas et al., 2010) 
4. Amniotic fluid derived cells and their role as cytokine modulators 
In the last years new evidences have been found that correlates the administration of stem 
cells with the modulation of inflammatory and fibrotic processes through cytokine mediated 
cross-talk between the pluripotent cells and the surrounding environment. New studies 
have highlighted the possibility that the same mechanism of action can be used to explain 
the effect of amniotic fluid stem cells in many diseases.  In particular, Perin showed that in a 
murine model of acute tubular necrosis, the expression of inflammatory cytokines is 
strongly regulated after injection of AFSC (Perin et al., 2010). Down regulation of pro-
inflammatory molecules and up-regulation of pro-regenerative and anti-flogistic cytokines 
resulted in a faster regeneration of the damaged tissue with higher proliferation rate, lower 
apoptosis and an overall better physiological profile of different renal parameters. A broad 
study performed by Yoon (Yoon et al., 2010) investigated the in vitro production of 
cytokines by AFMC in the cultured media. Presence of several inflammatory molecules was 
reported such as IL-8, IL-6, TGF-┚, TNFRI, VEGF, and EGF and other molecules involved in 
the TGFB/SMAD2 pathway. The conditioned culture media proved to be useful for 
enhancing wound healing in an in vivo murine model. While studying the angiogenic 
potential of AFSC, Teodolinda et al. (Teodolinda et al., 2011) reported the ability of the cells 
to produce and release several cytokines and chemoattractant molecules that are able to 
modulate not only the vessel growth but also the activity of macrophages/monocytes and 
other cells involved in inflammation and  immunoresponse.  
5. Conclusions 
In the last few years, an increasing number of studies have been performed on amniotic 
fluid derived stem cells and progenitor cells. Exciting results have been reported on 
amniotic fluid cell population characterization of composition, growth kinetics and potential 
for specific organ regeneration.  However, further investigation is still required to 
completely categorize cells according to origin and function.  Improving the efficiency and 
specificity of differentiation into various mature and functional cell types to prevent their 
attrition towards unrelated cell types would be an important factor to control in 
regenerative medicine applications. In this very same direction, the establishment of 
protocols and differentiative media will better allow us to compare the different populations 
and understand their mechanism of action. In addition, knowledge about how the different 
compartments of the developing fetus are contributing to the cellular composition may 
undisclose important information about the development and the amniotic fluid 
composition.  
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